{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:45:53Z","timestamp":1791395153218,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.bbrc.2008.01.019","type":"journal-article","created":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T07:21:36Z","timestamp":1200554496000},"page":"799-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Anticancer agent CHS-828 inhibits cellular synthesis of NAD"],"prefix":"10.1016","volume":"367","author":[{"given":"Uffe H\u00f8gh","family":"Olesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Knak","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Bj\u00f6rkling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"J\u00e4\u00e4ttel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Buhl","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sehested","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Jensby","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2008.01.019_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/bbrc.1999.0897","article-title":"Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity","volume":"260","author":"Frye","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2008.01.019_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Ame","year":"2004","journal-title":"Bioessays"},{"issue":"Pt 2","key":"10.1016\/j.bbrc.2008.01.019_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D\u2019Amours","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2008.01.019_bib4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1101\/gad.1467506","article-title":"Mammalian sirtuins\u2014emerging roles in physiology, aging, and calorie restriction","volume":"20","author":"Haigis","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2008.01.019_bib5","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1038\/sj.onc.1210616","article-title":"Sirtuins: critical regulators at the crossroads between cancer and aging","volume":"26","author":"Saunders","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2008.01.019_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ijc.20342","article-title":"Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions","volume":"111","author":"Beneke","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.01.019_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1126\/science.1072221","article-title":"Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor","volume":"297","author":"Yu","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2008.01.019_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2005.03.021","article-title":"Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia\/reperfusion","volume":"39","author":"van Wijk","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2008.01.019_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MOG.0b013e32801b3c8f","article-title":"The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt\/PBEF\/visfatin in mammals","volume":"23","author":"Revollo","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0027-5107(01)00078-1","article-title":"Niacin, poly(ADP-ribose) polymerase-1 and genomic stability","volume":"475","author":"Hageman","year":"2001","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2008.01.019_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1440-1746.2000.02193.x","article-title":"Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma","volume":"15","author":"Nomura","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10863-007-9070-5","article-title":"The cancer cell\u2019s \u201cpower plants\u201d as promising therapeutic targets: an overview","volume":"39","author":"Pedersen","year":"2007","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.bbrc.2008.01.019_bib14","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib15","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","author":"Holen","year":"2007","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbrc.2008.01.019_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nsmb1105","article-title":"Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents","volume":"13","author":"Khan","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib17","first-page":"5751","article-title":"CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo","volume":"59","author":"Hjarnaa","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","article-title":"Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG\/EORTC study","volume":"41","author":"Ravaud","year":"2005","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.bbrc.2008.01.019_bib19","first-page":"4431","article-title":"CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome","volume":"26","author":"Hassan","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.20255","article-title":"Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity","volume":"111","author":"Olsen","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.01.019_bib21","first-page":"6024","article-title":"Characterization of three new variant type cell lines derived from small cell carcinoma of the lung","volume":"45","author":"de Leij","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib22","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/0006-2952(93)90013-M","article-title":"Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance","volume":"45","author":"Jensen","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib23","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/S0960-894X(97)10152-4","article-title":"Novel cyanoguanidines with potent oral antitumour activity","volume":"7","author":"Schou","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2008.01.019_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1993.58","article-title":"Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines","volume":"67","author":"Jensen","year":"1993","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.bbrc.2008.01.019_bib25","first-page":"2269","article-title":"Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells","volume":"22","author":"Ekelund","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0006-2952(00)00382-8","article-title":"Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine","volume":"60","author":"Ekelund","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0006-2952(01)00570-6","article-title":"Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology","volume":"61","author":"Ekelund","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0959-8049(00)00375-0","article-title":"Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells","volume":"37","author":"Martinsson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2008.01.019_bib29","unstructured":"A. Roulston, C. Bernier, H. Chan, M.O. Gratton, A. Jang, E. Koch, M. Lavoie, D. Paquette, M. Mitchell, A. Berger, L. Belee, X. Billot, G. Shore, P. Beauparlant, in: Molecular Targets and Cancer Therapeutics, AACR, San Francisco, California, 2007, p. A81."},{"key":"10.1016\/j.bbrc.2008.01.019_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-2999(01)00925-6","article-title":"Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells","volume":"417","author":"Martinsson","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/sj.bjp.0704888","article-title":"The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro\u2014from cytotoxic synergy to complete inhibition of apoptosis","volume":"137","author":"Martinsson","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0006-2952(02)00890-0","article-title":"Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells","volume":"63","author":"Lovborg","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.01.019_bib33","first-page":"4211","article-title":"Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro","volume":"20","author":"Hansen","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2008.01.019_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00001813-200401000-00008","article-title":"Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828","volume":"15","author":"Gullbo","year":"2004","journal-title":"Anticancer Drugs"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X08000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X08000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:36:19Z","timestamp":1757759779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X08000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0006291X08000508"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2008.01.019","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer agent CHS-828 inhibits cellular synthesis of NAD","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2008.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}